American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

ASCO SIGN IN

Manage Email Subscriptions

Username:

Create an account

Why Be A Member?

Password:

Remember me

Forgot your username or password?

ASCO Membership Directory

The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

ASCO Home

Practice & Guidelines

Guidelines

Clinical Practice Guidelines

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Chemotherapy Sensitivity and Resistance Assays

Published in Journal of Clinical Oncology, Vol 29. No. 24. (August 20), 2011: pp.3328-3330

Harold J. Burstein, Pamela B. Mangu, Mark R. Somerfield, Deborah Schrag, David Samson, Lawrence Holt, Debra Zelman, and Jaffer A. Ajani

Objective: To update the American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays (CSRA) published in 2004.

Methods: An Update Working Group reviewed data published between December 1, 2003 and May 31, 2010. MEDLINE and the Cochrane Library were searched. The literature search yielded 11,313 new articles. The limits for “human and English” were used and then standard ASCO search strings for RCTs, meta-analyses, guidelines, and reviews were added, yielding 1,298 articles for abstract review. Of these, only 21 met predefined inclusion criteria and underwent full text review and 5 reports of RCTs were included for data extraction.

Results: Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice.

Recommendations: The use of chemotherapy sensitivity and resistance assays to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient’s health status and treatment preferences. Because the in-vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority.

To discuss this guideline, visit the ASCOconnection.org Practice forum. Log in with your asco.org username and password to comment.

The practice guideline is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients and may not reflect the most recent evidence. The guideline does not recommend any particular product or course of medical treatment. Use of the practice guideline and summary is voluntary. The full practice guideline and additional information are available at http://www.asco.org/guidelines.

Updated: 9/6/11